An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

HS Pandha; A Protheroe; J Wylie; C Parker; J Chambers; S Bell; G Munzert

$An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)$

Journal article

Peer reviewed

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

HS Pandha, A Protheroe, J Wylie, C Parker, J Chambers, S Bell and G Munzert

JOURNAL OF CLINICAL ONCOLOGY, Vol.26(15)

20/05/2008

Abstract

Science & Technology

Life Sciences & Biomedicine

Oncology

Files and links (1)

url

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000208457400842&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11d2a86992e85fb529977dad66a846d5View

Author

Metrics

45 Record Views

Details

Title: An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)
Creators: HS Pandha
A Protheroe
J Wylie
C Parker
J Chambers
S Bell
G Munzert
Publication Details: JOURNAL OF CLINICAL ONCOLOGY, Vol.26(15)
Publisher: AMER SOC CLINICAL ONCOLOGY
Date published: 20/05/2008
Date submitted: 17/05/2017
Identifiers: 99513720002346
Academic Unit: University of Surrey
Language: English
Resource Type: Journal article

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

Abstract

Files and links (1)

Metrics

Details

Usage Policy